Diffuse Reflectance Spectroscopy Can Help Assess Psoriasis Severity
Mexameter erythema readings are a good representation of skin oxygenated hemoglobin, but not deoxygenated hemoglobin.
Psoriasis Information Center
International Experts Urge Uniformity in Methotrexate Dosing for Psoriasis
An international consensus establishes methotrexate dosing recommendations for psoriasis treatment and identifies current knowledge gaps on the topic.
Site of Infection Associated With Increased Risk for PsA and Psoriasis
Researchers evaluated the association between pharyngeal infections and incident psoriatic arthritis and psoriasis.
IL-17 vs TNF Inhibitors for New Biologic Agent Users With Psoriatic Disease
The long-term persistence of various biologic agents in treating psoriasis and psoriatic arthritis are investigated.
Brodalumab Equally Effective in Treating Scalp, Nail Psoriasis in Men and Women
The efficacy of brodalumab by self-identified gender in patients with nail or scalp psoriasis is investigated.
Short-Term Air Pollution May Trigger Psoriasis Flares
Is short-term exposure to air pollutants associated with psoriasis flares?
Rate of Skin Clearance Linked to Quality of Life in Children With Psoriasis
Improvement in psoriasis clearance and its effect on pediatric patients’ quality of life is reviewed.
Top January 2022 FDA Drug Approvals
January 2022 FDA drug approvals include treatments for asthma, psoriatic arthritis, insomnia, and atopic dermatitis.
Modifiable Risk Factors and Cognitive Impairment in Patients With Psoriasis
Potential risk factors associated with cognitive impairment in patients with psoriasis are assessed.
Top August & September 2021 FDA Approvals
August and September 2021 FDA drug approvals include treatments for tick-borne encephalitis, idiopathic hypersomnia, schizophrenia, and atopic dermatitis.
Secukinumab vs Adalimumab in Concomitant PsA and Plaque Psoriasis
Secukinumab vs adalimumab for treatment in patients with concomitant plaque psoriasis and active psoriatic arthritis during 52 weeks is reported.
Psoriatic Arthritis Worsens QoL in Psoriasis Patients
Individuals with psoriasis/PsA have decreased ability to participate in social roles and activities, more depression symptoms.
Guselkumab Shows Skin Clearance in Psoriasis, Joint Symptom Improvement in Psoriatic Arthritis
At AAD VMX 2021, researchers presented data on skin clearance rates through 5 years with guselkumab in patients with moderate to severe plaque psoriasis.
Bimekizumab Tops Secukinumab for Plaque Psoriasis
In moderate-to-severe plaque psoriasis, bimekizumab is noninferior and superior to secukinumab and adalimumab, according to data from 2 studies.
Premature Mortality Not Associated With Chronic or Increasing Pain Among Patients With Psoriatic Arthritis
Researchers sought to determine if a higher cumulative pain intensity is associated with premature mortality risk in patients with PsA.
Similar Rates of Depression and Anxiety Plus Depression With Apremilast vs Other Drugs in Psoriatic Arthritis
Apremilast used for the treatment of psoriasis or psoriatic arthritis is not associated with a high risk of incident treated depression, anxiety, or anxiety plus depression.
Real-World Study: Guselkumab May Be Effective for Moderate to Severe Plaque Psoriasis
Real-world data from patients with plaque psoriasis treated with guselkumab, who had previously been administered biologic agents is presented.
Psoriasis Increases Risk for Metabolic Syndrome and Coronary Plaque Burden
A novel study evaluated the effect of cardiometabolic syndrome on early vascular disease in patients with psoriasis.
PASI, BSA Involvement, and QoL Scales Best to Determine Psoriasis Severity
The correlation between physician-evaluated PASI and BSA involvement and patient-evaluated DLQI and PDI was evaluated in measuring psoriasis disease severity.
Weight Loss Linked to Reduced Disease Activity in Patients With Psoriatic Arthritis and Obesity
Researchers assessed the effects of weight loss on disease activity and cardiovascular risk factors in patients with psoriatic arthritis and obesity.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Psoriasis Information Center
Loading... 
Loading...